Thursday, November 9, 2023 at 2-3 pm ET                 Pricing: Free for Members and Non-Members

Please note that this session is not accredited for continuing pharmacy education credit.

Program Description

This webinar explores the evolution of the treatment landscape, clinical outcomes, and practical management of a BCL2-Inhibitor. The content of this webinar is intended for US Formulary Decision Makers.

Learning Objectives

• Review the AML disease state and evolving treatment landscape.
• Describe the efficacy and safety of BCL2-inhibitor treatment in newly diagnosed AML unfit for intensive chemotherapy.
• Provide an overview of the practical management of AML patients receiving BCL2-inhibitor treatment.

This webinar is sponsored and developed by Abbvie US Medical Affairs. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.

Sponsored by:

For individuals from the media/press interested in attending, please email media@amcp.org.